Local drug delivery to the brain

Advanced Drug Delivery Reviews

Volumn 54, Issue 7, 2002, Pages 987-1013

  Wang, Paul P ^a   Frazier, James ^a   Brem, Henry ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Astrocytoma; BCNU; Brain tumor; Chemotherapy; Gliadel ; Glioblastoma multiforme; Glioma; Implantable polymer; Local drug delivery

Indexed keywords

BRAIN; CELLS; CHEMOTHERAPY; NEUROLOGY; POLYMERS; TUMORS;

NEOPLASMS;

CONTROLLED DRUG DELIVERY;

6 O BENZYLGUANINE; BLEOMYCIN; BRADYKININ ANTAGONIST; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE DERIVATIVE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IDOXURIDINE; LOBRADIMIL; LOMUSTINE; MANNITOL; METHOTREXATE; MINOCYCLINE; PACLITAXEL; SEMUSTINE;

BIOCOMPATIBILITY; BIOTECHNOLOGY; BLOOD BRAIN BARRIER; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0037120667     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00054-6     Document Type: Article

References (162)

1. Legler L.M., Gloeckler Ries L.A., Smith M.A., Warren L.L., Heineman E.F., Kaplan R.S., Linet M.S. Brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl. Cancer Inst. 91:1999;1382-1390.
2. Rostomily R., Keles G.E., Berger M.S. Radical surgery in the management of low-grade and high-grade gliomas. Bailliere's Clin. Neurol. 5:1996;345-369.
3. Chang C.H., Horton J., Schoenfeld D., Salazer O., Perez-Tamayo R., Kramer S., Weinstein A., Nelson J.S., Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer Res. 52:1983;997-1007.
4. Green S.B., Byar D.P., Walker M.D., Pistenmaa D.A., Alexander E.J., Batzdorf U., Brooks W.H., Hunt W.E., Mealey J.J., Odom G.L., Paoletti P., Ransohoff J.I., Robertson J.T., Selker R.G., Shapiro W.R., Jr S.K.R., Wilson C.B., Strike T.A. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. 67:1983;121-132.
5. Kornblith P.L., Walker M. Chemotherapy for malignant gliomas. J. Neurosurg. 68:1988;1-17.
6. Walker M.D., Green S.B., Byar D.P., Alexander E.J., Batzdorf U., Brooks W.H., Hunt W.E., MacCarty C.S., Mahaley M.S.J., Mealey J.J., Owens G., Ransohoff J.I., Robertson J.T., Shapiro W.R., Smith K.R.J., Wilson C.B., Strike T.A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303:1980;1323-1329.
7. Walker M.D., Alexander E.J., Hunt W.E., MacCarty C.S., Mahaley M.S.J., Mealey J.J., Norrell H.A., Owens G., Ransohoff J., Wilson C.B., Gehan E.A., Strike T.A. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49:1978;333-343.
8. Barker F.G., Chang S.M., Gutin P.H., Malek M.K., McDermott M.W., Prados M.D., Wilson C.B. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 42:1998;709-720.
9. Mohan D.S., Suh J.H., Phan J.L., Kupelian P.A., Cohen B.H., Barnett G.H. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary institution. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;981-987.
10. Reese T.S., Karnovsky M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34:1967;207-217.
11. Grieg N.H. Optimizing drug delivery to brain tumors. Cancer Treat. Rev. 14:1987;1-28.
12. Abbott N.J., Romero I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today. 2:1996;106-113.
13. Loo T.L., Dion R.L., Dixon R.L., Rall D.P. The antitumor agent, 1,3-bis(2-chloroethyl)-1-nitrosourea. J. Pharm. Sci. 55:1966;492-497.
14. Prokai L., Prokai-Tatrai K., Bodor N. Targeting drugs to the brain by redox chemical delivery systems. Med. Res. Rev. 20:2000;367-416.
15. Pardridge W.M. Vector-mediated drug delivery to the brain. Adv. Drug Deliv. Rev. 36:1999;299-321.
16. Williams P.C., Henner W.D., Roman-Goldstein S., Dahlborg S.A., Brummett R.E., Tableman M., Dana B.W., Neuwelt E.A. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms. Neurosurgery. 37:1995;17-28.
17. Warnke P.C., Blasberg R.G., Groothuis D.R. The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann. Neurol. 22:1987;300-305.
18. Sanovich E., Bartus R.T., Friden P.M., Dean R.L., Le H.Q., Brightman M.W. Pathway across blood-brain barrier opened by the bradykinin RMP-7. Brain Res. 705:1995;125-135.
19. Elliott P.J., Hayward N.J., Dean R.L., Blunt D.G., Bartus R.T. Intravenous RMP-7 selectively increases uptake of carboplatin in experimental brain tumors. Cancer Res. 56:1996;3998-4005.
20. Blasberg R.G. Methotrexate, cytosine arabinoside, and BCNU concentration in the brain after ventriculocisternal perfusion. Cancer Treat. Rep. 61:1977;625-631.
21. Ratcheson R.A., Ommaya A.K. Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N. Engl. J. Med. 279:1968;1025-1031.
22. Chandler W.F., Greenberg H.S., Ensminger W.D., Diaz R.F., Junck L.R., Hood T.W., Gebarski S.S., Page M.A. Use of implantable pump systems for intraarterial, intraventricular, and intratumoral treatment of malignant brain tumors. Ann. NY Acad. Sci. 531:1988;206-212.
23. Lord P., Allami H., Davis M., Diaz R., Heck P., Fischell R. MiniMed Technologies programmable implantable infusion system. Ann. NY Acad. Sci. 531:1988;66-71.
24. Heruth K.T. Medtronic SynchroMed drug administration system. Ann. NY Acad. Sci. 531:1988;72-75.
25. Langer R. New methods of drug delivery. Science. 249:1990;1527-1533.
26. Langer R., Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 263:1976;797-800.
27. Langer R., Brem H., Tapper D. Biocompatibility of polymeric delivery systems for macromolecules. J. Biomed. Mater. Res. 15:1981;267-277.
28. Tamargo R.J., Myseros J.S., Epstein J.I., Yang M.B., Chasin M., Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 53:1993;329-333.
29. Tamargo R.J., Sills A.K.J., Reinhard C.S., Pinn M.L., Long D.M., Brem H. Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J. Neurosurg. 74:1991;956-961.
30. Weingart J.D., Sipos E.P., Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J. Neurosurg. 82:1995;635-640.
31. Weingart J.D., Thompson R.C., Tyler B., Colvin O.M., Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int. J. Cancer. 62:1995;605-609.
32. Yang M.B., Tamargo R.J., Brem H. Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res. 49:1989;5103-5107.
33. Langer R.S., Wise D.L. Medical Applications of Controlled Release. 1984;CRC Press, Boca Raton, FL.
34. Brem H., Walter K., Langer R. Polymers as controlled drug delivery devices for the treatment of malignant brain tumors. Eur. J. Pharm. Biopharm. 27:1993;2-7.
35. Lewis D.H. Controlled release of bioactive agents from lactide/glycolide polymers. Chasin M., Langer R., Biodegradable Polymers as Drug Delivery Systems. 1990;1-41 Marcel Dekker, New York.
36. Frazza E.J., Schmitt E.E. A new absorbable suture. J. Biomed. Mater. Res. 5:1971;43-58.
37. Brady J.M., Cutright D.E., Miller R.A., Barristone G.C. Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J. Biomed. Mater. Res. 7:1973;155-166.
38. Kong Q., Kleinschmidt-Demasters B.K., Lillehei K.O. Intralesionally implanted cisplatin cures primary brain tumor in rats. J. Surg. Oncol. 64:1997;268-273.
39. Lillehei K.O., Kong Q., Withrow S.J., Kleinschmidt-Demasters B.K. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery. 39:1996;1191-1199.
40. Menei P., Daniel V., Montero-Menei C., Brouillardm M., Pouplard-Barthelaix A., Benoit J.P. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. Biomaterials. 14:1993;470-478.
41. Spenlehauer G., Vert M., Benoit J.P., Boddaert A. In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials. 10:1989;557-563.
42. Burt H.M., Jackson J.K., Bains S.K., Liggins R.T., Oktaba A.M., Arsenault A.L., Hunter W.L. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett. 88:1995;73-79.
43. Sato H., Wang Y.M., Adachi I., Horikoshi I. Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol. Pharm. Bull. 19:1996;1596-1601.
44. Peyman G.A., Conway M., Khoobehi B., Soike K. Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol. 16:1992;109-113.
45. Torres A.I., Boisdron-Celle M., Benoit J.P. Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure. J. Microencapsul. 13:1996;41-51.
46. Williams R.C., Paquette D.W., Offenbacher S., Adams D.F., Armitage G.C., Bray K., Caton J., Cochran D.L., Drisko C.H., Fiorellini J.P., Giannobile W.V., Grossi S., Guerrero D.M., Johnson G.K., Lamster I.B., Magnusson I., Oringer R.J., Persson G.R., Van Dyke T.E., Wolff L.F., Santucci E.A., Rodda B.E., Lessem J. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J. Periodontol. 72:2001;1535-1544.
47. Lamprecht A., Ubrich N., Yamamoto H., Schafer U., Takeuchi H., Maincent P., Kawashima Y., Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299:2001;775-781.
48. Lee M., Browneller R., Wu Z., Jung A., Ratanawong C., Sharifi R. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv. Drug Deliv. Rev. 28:1997;121-138.
49. Benoit J.P., Faisant N., Venier-Julienne M.C., Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J. Controlled Release. 65:2000;285-296.
50. Sugiyama T., Kumagai S., Nishida T., Ushijima K., Matsuo T., Yakushiji M., Hyon S.H., Ikada Y. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer. Anticancer Res. 18:1998;2837-2842.
51. Singh M., Saxena B.B., Singh R., Kaplan J., Ledger W.J. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres (NET-90): phase III clinical study. Adv. Contracept. 13:1997;1-11.
52. Menei P., Benoit J.P., Boisdron-Celle M., Fournier D., Mercier P., Guy G. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery. 34:1994;1058-1064.
53. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 263:1994;1600-1603.
54. H. Brem, R. Langer, Polymer-based drug delivery to the brain. Sci. Med., July/August (1996) 52-61.
55. Leong K.W., Brott B.C., Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J. Biomed. Mater. Res. 19:1985;941-955.
56. Chasin M., Domb A., Ron E. Polyanhydrides as drug delivery systems. Chasin M., Langer R., Biodegradable Polymers as Drug Delivery Systems. 1990;43-70 Marcel Dekker, New York.
57. Mathiowitz E., Saltzman M., Domb A. Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. J. Appl. Polym. Sci. 35:1988;755-774.
58. Mathiowitz E., Langer R. Polyanhydride microspheres as drug carriers. I. Hot-melt microencapsulation. J. Controlled Release. 5:1987;13-22.
59. Bindschaedler C., Leong K., Mathiowitz E., Langer R. Polyanhydride microsphere formulation by solvent extraction. J. Pharm. Sci. 77:1988;696-698.
60. Howard M.A. III, Gross A., Grady M.S., Langer R.S., Mathiowitz E., Winn H.R., Mayberg M.R. Intracerebral drug delivery in rats with lesion-induced memory deficits. J. Neurosurg. 71:1989;105-112.
61. Leong K.W., Kost J., Mathiowitz E., Langer R. Polyanhydrides for controlled release of bioactive agents. Biomaterials. 7:1986;364-371.
62. Mathiowitz E., Kline D., Langer R. Morphology of polyanhydride microsphere delivery systems. Scanning Microsc. 4:1990;329-340.
63. Leong K.W., D'Amore P.D., Marletta M., Langer R. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J. Biomed. Mater. Res. 20:1986;51-64.
64. Tamargo R.J., Epstein J.I., Reinhard C.S., Chasin M., Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J. Biomed. Mater. Res. 23:1989;253-266.
65. Brem H., Kader A., Epstein J.I., Tamargo R.J., Domb A., Langer R., Leong K.W. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel. Cancer Ther. 5:1989;55-65.
66. Brem H., Tamargo R.J., Olivi A., Pinn M., Weingart J.D., Wharam M., Epstein J.I. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J. Neurosurg. 80:1994;283-290.
67. Dang W., Saltzman W.M. Dextran retention in the rat brain following release from a polymer implant. Biotechnol. Prog. 8:1992;527-532.
68. Domb A., Bogdansky S., Olivi A., Judy K., Dureza C., Lenartz D., Pinn M.I., Colvin M., Brem H. Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants. Polym. Preprints. 32:1991;219-220.
69. Shieh L., Tamada J., Chen I., Pang J., Domb A., Langer R. Erosion of a new family of biodegradable polyanhydrides. J. Biomed. Mater. Res. 28:1994;1465-1475.
70. Tabata Y., Gutta S., Langer R. Controlled delivery systems for proteins using polyanhydride microspheres. Pharm. Res. 10:1993;487-496.
71. Tabata Y., Langer R. Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds. Pharm. Res. 10:1993;391-399.
72. Brem H., Domb A., Lenartz D., Dureza C., Olivi A., Epstein J.I. Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sebacic acid. J. Controlled Release. 19:1992;325-330.
73. Olivi A., Ewend M.G., Utsuki T., Tyler B., Domb A.J., Brat D.J., Brem H. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. Pharmacol. 39:1996;90-96.
74. Judy K.D., Olivi A., Buahin K.G., Domb A., Epstein J.I., Colvin O.M., Brem H. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg. 82:1995;481-486.
75. Shikani A.H., Eisele D.W., Domb A.J. Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 120:1994;1242-1247.
76. Gabizon A.A. Liposomal anthracyclines. Hematol. Oncol. Clin. North Am. 8:1994;431-450.
77. Golumbek P.T., Azhari R., Jaffee E.M., Levitsky H.I., Lazenby A., Leong K., Pardoll D.M. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53:1993;5841-5844.
78. Hirakawa W., Kadota K., Asakura T., Niiro M., Yokoyama S., Hirano H., Yatsushiro K., Kubota Y., Shimodozono Y. [Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue]. Gan To Kagaku Ryoho. 22:1995;805-809.
79. Ringkjob R. Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol. Scand. 44:1968;318-322.
80. Rama B., Mandel T., Jansen J., Dingeldein E., Mennel H.D. The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets. Acta Neurochir. 87:1987;70-75.
81. Oda Y., Tokuriki Y., Tsuda E., Handa H., Kieler J. Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic. Acta Neurochir. Suppl. 28:1979;489-490.
82. Grossman S.A., Reinhard C., Colvin O.M., Chasin M., Brundrett R., Tamargo R.J., Brem H. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 76:1992;640-647.
83. Fung L.K., Ewend M.G., Sills A., Sipos E.P., Thompson R., Watts M., Colvin O.M., Brem H., Saltzman W.M. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 58:1998;672-684.
84. Buahin K.G., Brem H. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. J. Neurooncol. 26:1995;103-110.
85. Sipos E.P., Tyler B., Piantadosi S., Burger P.C., Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol. 39:1997;383-389.
86. Ewend M.G., Williams J.A., Tabassi K., Tyler B.M., Babel K.M., Anderson R.C., Pinn M.L., Brat D.J., Brem H. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res. 56:1996;5217-5223.
87. Galicich J.H., Sundaresan N., Thaler H.T. Surgical treatment of single brain metastasis. Evaluation of results by computerized tomography scanning. J. Neurosurg. 53:1980;63-67.
88. Sawaya R., Ligon B.L., Bindal A.K., Bindal R.K., Hess K.R. Surgical treatment of metastatic brain tumors. J. Neurooncol. 27:1996;269-277.
89. Ewend M.G., Sampath P., Williams J.A., Tyler B.M., Brem H. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery. 43:1998;1185-1193.
90. Brem H., Mahaley M.S. Jr., Vick N.A., Black K.L., Schold S.C. Jr., Burger P.C., Friedman A.H., Ciric I.S., Eller T.W., Cozzens J.W., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74:1991;441-446.
91. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., Black K., Sisti M., Brem S., Mohr G., Muller P., Morawetz R., Schold S.C. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 345:1995;1008-1012.
92. Brem H., Ewend M.G., Piantadosi S., Greenhoot J., Burger P.C., Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J. Neurooncol. 26:1995;111-123.
93. Valtonen S., Timonen U., Toivanen P., Kalimo H., Kivipelto L., Heiskanen O., Unsgaard G., Kuurne T. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 41:1997;44-48.
94. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 58:1998;1068-1073.
95. 6-benzylguanine. Biochemistry. 32:1993;11998-12006.
96. 6-benzylguanine (NSC-637037) and BCNU (carmustine, NSC-409962) in male and female beagle dogs, in: Proc. Am. Assoc. Cancer Res. 35 (1994) 1952.
97. 6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 60:2000;6307-6310.
98. Cahan M.A., Walter K.A., Colvin O.M., Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother. Pharmacol. 33:1994;441-444.
99. Klecker R., Jamis-Dow C., Egorin M. Distribution and metabolism of 3-H Taxol in the rat (Abstract). Proc. Am. Assoc. Cancer Res. 34:1992;381.
100. Walter K.A., Cahan M.A., Gur A., Tyler B., Hilton J., Colvin O.M., Burger P.C., Domb A., Brem H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 54:1994;2207-2212.
101. Harper E., Lapidus R.G., Garver R.I. Jr. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin. Cancer Res. 5:1999;4242-4248.
102. P. Gabikian, K.W. Li, C. Magee, C. Morrell, B.M. Tyler, F. Foster, W. Dang, H. Brem, K.A. Walter, Safety of Intracranial Paclitaxel:Polilactofate Microspheres in Dogs (Poster), in: American Association of Neurological Surgeons Annual Meeting, 2002, Chicago, IL.
103. Chabner B.A., Collins J.M., Cancer Chemotherapy: Principles and Practice. 1990;J.B. Lippincott, Philadelphia, PA.
104. Colvin M., Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep. 65:(Suppl. 3):1981;89-95.
105. Buahin K.G., Judy K.D., Hartke C., et al. Controlled release of 4-hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer. Polym. Adv. Technol. 3:1993;311.
106. Sipos E.P., Witham T.F., Ratan R., Burger P.C., Baraban J., Li K.W., Piantadosi S., Brem H. L-Buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model. Neurosurgery. 48:2001;392-400.
107. Colvin O.M., Friedman H.S., Gamcsik M.P., Fenselau C., Hilton J. Role of glutathione in cellular resistance to alkylating agents. Adv. Enzyme Regul. 33:1993;19-26.
108. Goodman L.S., Hardman J.G., Limbird L.E., Gilman A.G. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 2001;McGraw-Hill, New York.
109. Levin V.A., Edwards M.S., Wara W.M., Allen J., Ortega J., Vestnys P. 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. Neurosurgery. 14:1984;679-681.
110. Shapiro W.R. Studies on the chemotherapy of experimental brain tumors: evaluation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine, and 5-fluorouracil. J. Natl. Cancer Inst. 46:1971;359-368.
111. Shapiro W.R., Green S.B., Burger P.C., Selker R.G., VanGilder J.C., Robertson J.T., Mealey J. Jr., Ransohff J., Mahaley M.S. Jr. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J. Neurosurg. 76:1992;772-781.
112. Oda Y., Uchida Y., Murata T., Mori K., Tokuriki Y., Handa H., Kobayashi A., Hashi K., Kieler J. [Treatment of brain tumors with anticancer pellet - experimental and clinical study (author's translation)]. No Shinkei Geka. 10:1982;375-381.
113. Oda Y., Kamijyo Y., Okumura T., Tokuriki Y., Yamashita J., Handa H., Aoyama I., Hashi K., Mori K. [Clinical application of a sustained release anticancer pellet]. No Shinkei Geka. 13:1985;1305-1311.
114. Kubo O., Himuro H., Inoue N., Tajika Y., Tajika T., Tohyama T., Sakairi M., Yoshida M., Kaetsu I., Kitamura K. [Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites]. No Shinkei Geka. 14:1986;1189-1195.
115. Boisdron-Celle M., Menei P., Benoit J.P. Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J. Pharm. Pharmacol. 47:1995;108-114.
116. Menei P., Boisdron-Celle M., Croue A., Guy G., Benoit J.P. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery. 39:1996;117-124.
117. Menei P., Venier M.C., Gamelin E., Saint-Andre J.P., Hayek G., Jadaud E., Fournier D., Mercier P., Guy G., Benoit J.P. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer. 86:1999;325-330.
118. M.A. Choti, J. Saenz, X. Yang, H. Brem, Intrahepatic FUdR delivered from biodegradable polymer in experimental liver metastases from colorectal carcinoma, in Proc. Am. Assoc. Cancer Res. 36 (1995) 309.
119. Damascelli B., Marchiano A., Frigerio L.F., Salvetti M., Spreafico C., Garbagnati F., Zanoni F., Radice F. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma. Cancer. 68:1991;995-998.
120. Nakazawa S., Itoh Y., Shimura T., Matsumoto M., Yajima K. [New management of brain neoplasms. 2. Local injection of adriamycin]. No Shinkei Geka. 11:1983;821-827.
121. Lin S.Y., Lui W.Y., Chen C.F., Han S.H. Tumoricidal effect of controlled-release polymeric needle devices containing adriamycin HCl in tumor-bearing mice. Biomater. Artif. Cells Artif. Organs. 17:1989;189-203.
122. M.C. Watts, M.S. Lesniak, M. Burke, A.F. Samdani, B.M. Tyler, H. Brem, Controlled release of adriamycin in the treatment of malignant glioma (Poster), in: American Association of Neurological Surgeons Annual Meeting, 1997, Denver, CO.
123. Sendelbeck S.L., Urquhart J. Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Res. 328:1985;251-258.
124. Blasberg R.G., Patlak C.S., Shapiro W.R. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat. Rep. 61:1977;633-641.
125. Diemath H.E. [Local use of cytostatic drugs following removal of glioblastomas]. Wien. Klin. Wochenschr. 99:1987;674-676.
126. Dang W., Colvin O.M., Brem H., Saltzman W.M. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res. 54:1994;1729-1735.
127. Zeller W.J., Bauer S., Remmele T., Wowra B., Sturm V., Stricker H. Interstitial chemotherapy of experimental gliomas. Cancer Treat. Rep. 7:1990;183-189.
128. Weiss S.R., Raskind R. Treatment of malignant brain tumors by local methotrexate. A preliminary report. Int. Surg. 51:1969;149-155.
129. Uldry P.A., Teta D., Regli L. [Focal cerebral necrosis caused by intraventricular chemotherapy with methotrexate]. Neurochirurgie. 37:1991;72-74.
130. Shimura T., Nakazawa S., Ikeda Y., Node Y. [Cyst formation following local chemotherapy of malignant brain tumor: a clinicopathological study of two cases]. No Shinkei Geka. 20:1992;1179-1183.
131. Olivi A., Gilbert M., Duncan K.L., Corden B., Lenartz D., Brem H. Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother. Pharmacol. 31:1993;449-454.
132. Utsuki T., Brem H., Pitha J., Loftsson T., Kristmundsdottir T., Tyler B.T., Olivi A. Potentiation of anti-cancer effects of microencapsulated carboplatin by hydroxypropyl α-cyclodextrin. J. Controlled Release. 40:1996;251-260.
133. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
134. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., Kaufmann S.H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:1993;271-291.
135. Storm P.B., Moriarity J.L., Tyler B., Burger P.C., Brem H., Weingart J.D. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J. Neurooncol. 56:2002;209-217.
136. Katakura R., Mori T., Mineura K., Suzuki J. [A device for prolonged releasing of anticancer drug - bleomycin (author's translation)]. No Shinkei Geka. 8:1980;1057-1062.
137. Katakura R., Mori T., Suzuki J. [A device for prolonged releasing of anticancer drug - bleomycin: Second report]. No Shinkei Geka. 10:1982;941-944.
138. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
139. Gimbrone M.A. Jr., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:1972;261-276.
140. Tamargo R.J., Leong K.W., Brem H. Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J. Neurooncol. 9:1990;131-138.
141. Folkman J., Langer R., Linhardt R.J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 221:1983;719-725.
142. Golub L.M., Wolff M., Lee H.M., McNamara T.F., Ramamurthy N.S., Zambon J., Ciancio S. Further evidence that tetracyclines inhibit collagenase activity in human cervicular fluid and from other mammalian sources. J. Periodontal Res. 20:1985;12-23.
143. Tamargo R.J., Bok R.A., Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51:1991;672-675.
144. Sills A.K. Jr., Williams J.I., Tyler B.M., Epstein D.S., Sipos E.P., Davis J.D., McLane M.P., Pitchford S., Cheshire K., Gannon F.H., Kinney W.A., Chao T.L., Donowitz M., Laterra J., Zasloff M., Brem H. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. 58:1998;2784-2792.
145. Bhargava P., Marshall J.L., Dahut W., Rizvi N., Trocky N., Williams J.I., Hait H., Song S., Holroyd K.J., Hawkins M.J. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin. Cancer Res. 7:2001;3912-3919.
146. Maxell R.E., Long D.M., French L.A. The clinical effects of a synthetic gluco-corticoid used for brain edema in the practice of neurosurgery. Reulen H.J., Schurmann K., Steroids and Brain Edema. 1972;219-232 Springer, Berlin.
147. Melby J.C. Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann. Intern. Med. 81:1974;505-512.
148. Reinhard C.S., Radomsky M.L., Saltzman W.M., et al. Polymeric controlled release of dexamethasone in normal rat brain. J. Controlled Release. 16:1991;331-340.
149. Thompson R.C., Pardoll D.M., Jaffee E.M., Ewend M.G., Thomas M.C., Tyler B.M., Brem H. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. Emphasis Tumor Immunol. 19:1996;405-413.
150. Ewend M.G., Thompson R.C., Anderson R., Sills A.K., Staveley-O'Carroll K., Tyler B.M., Hanes J., Brat D., Thomas M., Jaffee E.M., Pardoll D.M., Brem H. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J. Immunother. 23:2000;438-448.
151. DiMeco F., Rhines L.D., Hanes J., Tyler B.M., Brat D., Torchiana E., Guarnieri M., Colombo M.P., Pardoll D.M., Finocchiaro G., Brem H., Olivi A. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J. Neurosurg. 92:2000;419-427.
152. Sampath P., Hanes J., DiMeco F., Tyler B.M., Brat D., Pardoll D.M., Brem H. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res. 59:1999;2107-2114.
153. Hanes J., Sills A., Zhao Z., Suh K.W., Tyler B., DiMeco F., Brat D.J., Choti M.A., Leong K.W., Pardoll D.M., Brem H. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm. Res. 18:2001;899-906.
154. Williams J.A., Dillehay L.E., Tabassi K., Sipos E., Fahlman C., Brem H. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J. Neurooncol. 32:1997;181-192.
155. Williams J.A., Yuan X., Dillehay L.E., Shastri V.R., Brem H., Williams J.R. Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;631-639.
156. R.J. Tamargo, L.A. Rossell, B.M. Tyler, J.J. Aryanpur, Interstitial delivery of diphenylhydantoin in the brain for the treatment of seizures in the rat model (Poster), in: American Association of Neurological Surgeons Annual Meeting, 1994, San Diego, CA.
157. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA. 91:1994;2076-2080.
158. Laske D.W., Morrison P.F., Lieberman D.M., Corthesy M.E., Reynolds J.C., Stewart-Henney P.A., Koong S.S., Cummins A., Paik C.H., Oldfield E.H. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J. Neurosurg. 87:1997;586-594.
159. Lieberman D.M., Corthesy M.E., Cummins A., Oldfield E.H. Reversal of experimental parkinsonism using selective chemical ablation of the medial globus pallidus. J. Neurosurg. 90:1999;928-934.
160. Lonser R.R., Gogate N., Morrison P.F., Wood J.D., Oldfield E.H. Direct convective delivery of macromolecules to the spinal cord. J. Neurosurg. 89:1998;616-622.
161. Mardor Y., Roth Y., Lidar Z., Jonas T., Pfeffer R., Maier S.E., Faibel M., Nass D., Hadani M., Orenstein A., Cohen J.S., Ram Z. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 61:2001;4971-4973.
162. Santini J.T. Jr., Richards A.C., Scheidt R.A., Cima M.J., Langer R.S.